Current Price{{movement}} ${{quote.Last.toFixed(3) == 0.000 ? quote['CF CLOSE'].toFixed(3) : quote.Last.toFixed(3)}} (20 minute delay)
Today's Change ${{quote['Net Change'].toFixed(3)}} ({{quote['% Change']}}%) Market is currently: {{(quote['Price Qualifier Code'] == 'OPN' || quote['Price Qualifier Code'] == 'SUS') ? "OPEN" : "CLOSED"}}
Open {{quote['Opening Price'].toFixed(3)}} Prev Close {{quote['Historic Close'].toFixed(3)}}
Today's High {{quote["Today's High"].toFixed(3)}} Today's Low {{quote["Today's Low"].toFixed(3)}}
Broker Consensus

No Data Available

  • Sell
  • Reduce
  • Hold
  • Buy
  • Strong Buy

Activistic Limited (ACU)
is a publicly listed company on the Australian Securities Exchange (ASX).


General Overview

About Activistic Limited

Acuvax Ltd (ASX: ACU) is in the process of acquiring Biolife Science Ltd, which is developing a vaccine for breast and gastric cancers. On 22 March 2013, Acuvax shareholders voted overwhlemingly to approve the acquisition of Biolife and to raise $5m to fund Phase 2 trials of the vaccine.

The shares of Acuvax are currently suspended from ASX pending the completion of the capital raising, the consolidation of shares and re-admission to ASX.

Biolife has secured the rights to acquire intellectual property related to the development of a vaccine for HER-2 positive cancers. HER-2 is a receptor that is responsible for regulating cell division and, when over-expressed, results in uncontrolled cell division.

The vaccine, known as HER-Vaxx, comprise three peptides that, when injected, induce the body's B cells to produce a regular stream of polyclonal antibodies that block the HER-2 signalling mechanism.

HER-2 is over-expressed in approximately 15% of invasive breast cancers, 54-100% of colorectal cancers, 25% of ovarian cancers, 17-82% of pancreatic cancers and 34% of prostate cancers.

The current primary treatment is a monoclonal antibody, such as Herceptin, combined with chemotherapy. Herceptin has annual sales of over US$5 billion. HER-Vaxx is designed to act in a similar fashion to Herceptin but is also designed to bind to other epitopes on the receptor giving it the potential to be more effective, longer lasting and, therefore, more cost effective.

Contact Info

Activistic Limited

Suite 2
16 Ord Street
West Perth, WA
AU Australia, 6005

Phone: +61 8 9429 2900
Fax: +61 8 9486 1011

Click here to view the interactive map
Activistic Limited Google Map
Activistic Limited Google Map

Share Registry

Security Transfer Registrars Pty. Ltd - Click here to view share registry profile

Phone: +61 8 9315 2333
Fax: +61 8 9315 2233

770 Canning Highway
Applecross, WA
AU Australia, 6153

Important Information

The General Overview, Services, Products and Projects information for this profile was last edited on 05 Feb 2016.

All Financial Data is provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Share Prices nor any independent data provider is liable for any informational errors, omissions or other defects, incompleteness, or delays, or for any actions taken in reliance on Financial Data.

Please read our Terms & Conditions and Disclaimer Statement for further information.




Report a bug